Skip to main content

Novel Rx

      PD-1 agonist as an induction therapy in refractory RA??

      Rosnilimab ph2b:
      - still responding 3mo after Rx stopped
      - no d

      David Liew drdavidliew

      6 days 6 hours ago
      PD-1 agonist as an induction therapy in refractory RA?? Rosnilimab ph2b: - still responding 3mo after Rx stopped - no difference between type of prior b/tsDMARD failure - safety here looks good *so far* A lot of cautious excitement in the room for this #ACR25 LB19 @RheumNow https://t.co/CmfPlP4g0N
      A new approach in RA:

      Rosnilimab targets & depletes PD-1–high pathogenic T cells, acting upstream of cytokine pa

      Jiha Lee JihaRheum

      6 days 6 hours ago
      A new approach in RA: Rosnilimab targets & depletes PD-1–high pathogenic T cells, acting upstream of cytokine pathways. In Ph2b, all doses improved DAS28-CRP & ACR responses vs placebo, with durable efficacy & good safety. @RheumNow #ACR25 Abstract#LB19 https://t.co/cIxi7NEu6C
      #ACR25 Abstr#LB19 New T-cell therapy on the block! In Phase 2b RCT of #RA (~50% b/tsDMARD-IR), Rosnilimab, PD-1 agonist

      Md Yuzaiful Md Yusof Yuz6Yusof

      6 days 6 hours ago
      #ACR25 Abstr#LB19 New T-cell therapy on the block! In Phase 2b RCT of #RA (~50% b/tsDMARD-IR), Rosnilimab, PD-1 agonist met its endpoint (DAS28-CRP) at WK12. Effective despite type of previous therapy. No safety concern/malignancy/death. To proceed to Phase 3 @RheumNow #ACRBest https://t.co/MecTYMpH0o
      Emery et al. Rosnilimab, selective T cell (PD-1high Tph/Tfh, Teff) monoclonal antibody in RA. Phase 2 RCT. 424 patients.

      Richard Conway RichardPAConway

      6 days 6 hours ago
      Emery et al. Rosnilimab, selective T cell (PD-1high Tph/Tfh, Teff) monoclonal antibody in RA. Phase 2 RCT. 424 patients. 41% prior bDMARD. 69% CDAI LDA week 14. Week 12 ACR20 70%, ACR50 40%, ACR70 21%. @RheumNow #ACR25 Abstr#LB19 https://t.co/479q6COWvk
      ROC-SpA Study
      Psoriatic arthritis (PsA) is a complex inflammatory disease often complicated by obesity, which not only worsens disease activity but also impairs treatment response. At ACR Convergence 2025, three compelling studies spanning pharmacologic, lifestyle, and longitudinal observational data converged on a central theme: weight loss is a powerful modulator of PsA outcomes, regardless of the intervention used.
      IgG4 is a rare autoimmune disease with excessive IgG4 immunoglobulins that can affect multiple organs yielding plasma cell deposition (inflammation) and fibrosis.There has been great progress in treatment. Traditionally, glucocorticoids were used and if ineffective, then an oral immunesuppressive (ex: Azathioprine, MMF) and, if needed, rituximab. Many patients can improve sufficiently on this regimen.
      #ACR25 Abstr#LB14 Promising therapyBMS-986353, a CD19 CAR-T in Severe Refractory Idiopathic Inflammatory Myopathies. 11

      Md Yuzaiful Md Yusof Yuz6Yusof

      6 days 10 hours ago

      #ACR25 Abstr#LB14 Promising therapy BMS-986353, a CD19 CAR-T in Severe Refractory Idiopathic Inflammatory Myopathies. 11/12 had evaluable data; muscle, skin and ILD improved. 1 x G2 CRS, 1 G3 ICANS. Longer FU needed and larger sample @RheumNow https://t.co/zAG23tAsbL

      What's the latest in PsA?
      IgG4: Rare but Treatable!
      Post-hoc analysis of CARE study comparing effect of Cenerimod 4mg vs. PBO

      Mos. 4-6: >10% improvement in alopecia w/

      sheila RHEUMarampa

      1 week ago
      Post-hoc analysis of CARE study comparing effect of Cenerimod 4mg vs. PBO Mos. 4-6: >10% improvement in alopecia w/Cenerimod Mos. 2-6: >10% improvement in mucosal ulcers w/ Cenerimod Early improvement in alopecia & ulcers w/Cenerimod Promising? #ACR25 @RheumNow Abs2440 https://t.co/mAqmIQashr
      What's new in sjogren's?

      Promising phase III data of telitacicept (dual BLyS + APRIL neutralization)

      Pt in both dosing

      Brian Jaros, MD Dr_Brian_MD

      1 week ago
      What's new in sjogren's? Promising phase III data of telitacicept (dual BLyS + APRIL neutralization) Pt in both dosing groups with decrease in ESSDAI compared to PBO but best results at higher (160mg) dose Similar rates of adverse events @RheumNow #ACR25 Abst LB11 https://t.co/r9JaVKzedH
      @RheumNow Plus a heap more biosimilars have broken through in the US in the last year. It feels the biosimilar era is no

      David Liew drdavidliew

      1 week ago
      @RheumNow Plus a heap more biosimilars have broken through in the US in the last year. It feels the biosimilar era is now here stateside, too. #ACR25 FDA Update @RheumNow https://t.co/9RiyhbKXU4
      ×